DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
By integrating Rockwell Automation’s FactoryTalk Optix, NKP Pharma has achieved compliance with USFDA 21 CFR Part 11
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
The unique soap-fusion of Gondhoraj lime and neem provides a refreshing skin-friendly experience
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Subscribe To Our Newsletter & Stay Updated
